(Reuters) – The U.S. Food and Drug Administration on Monday declined to approve Intercept Pharmaceuticals Inc’s therapy for a progressive liver disease, creating a setback for a possible treatment in the country for the condition that affects millions. (https://reut.rs/2ZhKnbP)
The therapy, chemically known as obeticholic acid, is designed to improve fibrosis, or the build up of scar tissue in the liver caused by non-alcoholic steatohepatitis, a chronic disease related to obesity.
(Reporting by Saumya Sibi Joseph and Trisha Roy in Bengaluru; Editing by Arun Koyyur)
